Montag & Caldwell LLC Purchases 4,934 Shares of Zoetis Inc. (NYSE:ZTS)

Montag & Caldwell LLC increased its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 4.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,832 shares of the company’s stock after purchasing an additional 4,934 shares during the quarter. Zoetis makes up approximately 4.3% of Montag & Caldwell LLC’s holdings, making the stock its 6th biggest holding. Montag & Caldwell LLC’s holdings in Zoetis were worth $21,468,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Webster Bank N. A. increased its stake in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Zoetis in the fourth quarter worth about $40,000. LRI Investments LLC acquired a new position in shares of Zoetis during the first quarter worth approximately $43,000. Blue Bell Private Wealth Management LLC grew its stake in shares of Zoetis by 111.6% during the first quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock valued at $46,000 after purchasing an additional 144 shares during the last quarter. Finally, Hazlett Burt & Watson Inc. increased its holdings in shares of Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after purchasing an additional 102 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS opened at $191.09 on Monday. The firm has a market cap of $86.57 billion, a P/E ratio of 36.82, a PEG ratio of 2.92 and a beta of 0.88. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The firm’s 50 day moving average price is $182.85 and its two-hundred day moving average price is $174.14.

Zoetis (NYSE:ZTSGet Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. During the same period in the prior year, the business earned $1.41 EPS. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZTS. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $217.11.

Read Our Latest Stock Analysis on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.